Global HOPE is a transformational initiative to dramatically improve the diagnosis and treatment of children with cancer and blood diseases in sub-Saharan Africa by training African doctors and nurses, improving access to medicine, and strengthening healthcare infrastructure. Global HOPE has established treatment and training centers in Botswana, Malawi, Tanzania, and Uganda, and is expanding to other countries where doctors have been trained. At Teva, we have the largest generic medicines portfolio and manufacture 73% of cancer therapies on the WHO List of Essential Medicines. Through this partnership, Teva provides 22 medicines that help cure children, prevent patients from suffering, and live better lives.

The World Health Organization (WHO) estimates more than 80% of children with cancer are cured in high-income countries, while less than 30% are cured in low-and-middle-income countries (LMICs). Only 29% of low-income countries report cancer medicines generally available to their populations, compared to 96% of high-income countries.

The Republic of Malawi alone ranks among the world’s most densely populated, poorest and least developed countries—with 67% of the country’s 17.9 million people under the age of 24. The burden of pediatric cancer and blood disorders is significant – roughly 5,200 children develop cancer and most die of their disease without ever receiving care or a proper diagnosis.

The program has increased the number of patients treated, increased survival rates and helped train healthcare workers. In 2022, we supplied more than 290,000 doses of medicine (valued at USD $5M) through this program.